Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESHAOX for Refractory or Relapsed Non-Hodgkin's Lymphoma
NCT00336583Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- Jun 2006
- Primary completion
- Dec 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in non-Hodgkin lymphoma (NHL), sponsored by Asan Medical Center. Primary endpoint: Overall Response Rate at 24 weeks. Started Jun 2006; status: completed.
02
Drugs
oxaliplatin
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00336583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00336583.